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Management of  
Type II Endoleaks
A
ccording to the National Surgical Quality 
Improvement Program, 75% of abdominal 
aortic aneurysms are treated with endovascu-
lar techniques compared to open repair,1 as 
endovascular aneurysm repair (EVAR) is associated with 
decreased periprocedural mortality, complications, and 
length of hospital stay.2,3 However, some studies have 
shown an increased rate of reinterventions in EVAR com-
pared to open repair,4,5 a percentage of which are due to 
aneurysm growth secondary to an endoleak. Endoleaks 
can occur in up to 20% to 25% of patients after EVAR,6,7 
with type II endoleaks being the most common. 
Type II endoleaks account for at least 40% of all endole-
aks.8 They commonly occur from retrograde collateral 
blood flow into the aneurysm sac, typically from a lumbar 
artery or the inferior mesenteric artery (IMA).9 Less com-
mon sources of type II endoleaks include accessory renal 
and median sacral arteries. In patients who require endo-
graft limb extension across the internal iliac artery, this vessel 
can also serve as a source of endoleak if it is not adequately 
embolized. Endoleaks can lead to enlargement and pres-
surization of the sac, leading to rupture (which is uncom-
mon). The retrograde collateral blood flow may or may not 
result in sac pressurization, as not all of these endoleaks are 
associated with aneurysm growth. Type II endoleaks can be 
subdivided into type IIa, which has a single causative vessel 
involved with “to-and-fro” flow in the aneurysm sac, and 
type IIb, in which multiple vessels are involved. 
NATURAL HISTORY OF TYPE II ENDOLEAKS
Compared to other endoleaks, type II endoleaks generally 
have a benign course, and many spontaneously resolve. In 
our experience, type IIa endoleaks have a greater propensity 
to spontaneously resolve than type IIb, which tend to be 
more complex. In one study, only 19% of type II endoleaks 
were associated with aneurysm growth requiring interven-
tion.10 In another study, only 20% required intervention.11 
However, it has been demonstrated that the presence of 
a persistent type II endoleak is associated with aneurysm 
sac growth, increased reintervention rates, conversion 
to open repair, and aneurysm sac rupture.12 A persistent 
type II endoleak is described as persisting beyond 6 months. 
Predictors of a persistent type II endoleak include a patent 
IMA > 2.5 mm in diameter, a lumbar artery > 1.9 mm in 
diameter, and more than two lumbar arteries that extend 
from the aneurysm sac.13,14
FOLLOW-UP AFTER EVAR AND ENDOLEAK 
EVALUATION
After EVAR has been completed, our follow-up protocol 
consists of CT angiography (CTA) at 1, 6, and 12 months, 
and annually thereafter. Some patients may be followed 
every 2 years, especially in the setting of a shrinking sac in 
the absence of an endoleak. Patients with renal insufficiency 
may be followed with duplex ultrasound and noncontrast 
CT. Time-resolved magnetic resonance angiography is used 
selectively at our center, sometimes to better determine the 
flow dynamics of an endoleak seen on CTA.
It is critical that a proper imaging protocol is utilized for 
cross-sectional imaging after EVAR to ensure that endoleaks 
are identified. A three-phase scan consisting of a noncon-
trast scan, an arterial phase, and delayed imaging is essen-
tial, and review of previous studies is mandatory. Once an 
endoleak is identified, it is critical to determine the endoleak 
type in order to guide management. Although cross-sec-
tional imaging can diagnose the presence of an endoleak, 
the type of endoleak is not always evident on cross-sectional 
imaging alone. In these cases, diagnostic angiography is 
required to determine the precise etiology in order to 
guide subsequent therapy. Diagnostic angiography should 
include an aortogram, as well as selective angiography of the 
superior mesenteric artery (SMA) and bilateral internal iliac 
arteries. If a type III endoleak is suspected, angiography per-
formed with a pigtail catheter placed within the endograft 
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may be useful. Another useful technique is placement of an 
occlusion balloon above the pigtail catheter in the graft to 
increase the sensitivity for type III endoleak assessment. The 
latter strategy is also useful in identifying a type Ib endoleak 
by deploying a compliant balloon in the iliac limb and per-
forming power injection angiography at the distal seal site. If 
a significant amount of contrast or radiation dose has been 
utilized during these diagnostic procedures, it is not unrea-
sonable to stage the therapy with the treatment procedure 
performed on a later date once the endoleak type and etiol-
ogy are determined. 
It is important to note that the presence of one type 
of endoleak does not exclude a second type of endoleak. 
Endoleaks are often complex, and successful treatment 
of one endoleak does not preclude later development of 
another. Therefore, longitudinal follow-up of these patients 
is mandatory. Furthermore, filling of the IMA or lumbar 
arteries on cross-sectional imaging does not always repre-
sent a type II endoleak; we have seen many patients who 
have a subtle type Ia endoleak with resultant antegrade flow 
in these vessels (inflow from the proximal attachment zone 
and outflow from the lumbar/IMA), which is best appreci-
ated on aortography. 
 
TREATMENT APPROACH
At Miami Cardiac and Vascular Institute, type II endole-
aks are only treated if there is evidence of aneurysm growth 
(generally > 5 mm). There are multiple approaches to the 
management of these endoleaks, including transarterial, 
translumbar, transcaval, and surgical approaches.
 
Transarterial Embolization
The transarterial and translumbar approaches are most 
commonly used to address these endoleaks, and there are 
conflicting data on which technique is more effective. The 
transarterial approach is our preferred first-line therapy 
Figure 1.  A patient with a type II endoleak via a right lumbar artery (A) and enlarging aortic sac. Angiogram showing a pig-
tail catheter in the right limb of a bifurcated endograft demonstrates an endoleak being fed by a lumbar artery (arrow) (B). 
A 5-F Cobra 2 catheter was placed into the right hypogastric artery, and angiography via a microcatheter placed into the 
culprit lumbar artery through the iliolumbar collateral better delineates the endoleak (C). Onyx was administered through 
the microcatheter (D). Further embolization was carried out until there was complete filling of the endoleak sac, as well as 
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to manage these endoleaks. It is important to stress that 
persistent type II endoleaks associated with aneurysm 
enlargement typically behave like arteriovenous malforma-
tions, with multiple ingress and egress vessels. Treatment 
of the nidus, or endoleak sac, is critical for an effective and 
durable result. The challenge lies in the ability to advance 
a microcatheter in a retrograde manner from the SMA 
(via the arc of Riolan or marginal artery of Drummond) 
to the IMA or from the internal iliac artery (via the ilio-
lumbar artery) to the culprit lumbar artery. It is essential 
to advance the microcatheter to the aneurysm sac; how-
ever, these collateral pathways can be long and extremely 
tortuous, which can be difficult and sometimes impos-
sible to navigate. Complete obliteration of the endoleak 
nidus with elimination of all inflow and outflow vessels is 
required to prevent recurrence. Proximal embolization is 
not recommended, as the type II endoleak will recur by 
recruiting additional aortic branch vessels, possibly making 
the treatment even more complex. 
Stable access in the SMA or internal iliac artery is the 
first important step in performing transarterial emboliza-
tion. A 5-F Cobra catheter or reverse-curve catheter (ie, Sos, 
Simmons) are our initial “go-to” catheters. In the setting 
of significant tortuosity and an inability to achieve stable 
access with these catheters, steerable guiding sheaths such 
as the Destino (Oscor Inc.) or Morph (BioCardia, Inc.) cath-
eter, or the Magellan robotic catheter (Hansen Medical, Inc.) 
can be valuable. A 150-cm-long microcatheter with a 0.021-
inch inner diameter or smaller is recommended. We typical-
ly use a dimethylsulfoxide-compatible microcatheter such 
as Echelon or Rebar (Medtronic) to allow treatment with 
the Onyx liquid embolic system (Medtronic). Although the 
Progreat microcatheter (Terumo Interventional Systems) 
is not validated as dimethylsulfoxide compatible, we have 
not encountered any problem injecting Onyx through it. 
We typically use coils and/or Onyx to treat the majority of 
these endoleaks. One potential benefit of Onyx is the ability 
to advance beyond the site of delivery and disperse through 
the endoleak nidus/sac to fill the ingress and egress vessels 
(Figure 1). Because Onyx is radiopaque, it can be closely 
followed under fluoroscopic guidance, and injection may 
be stopped if there is inadvertent nontarget delivery of the 
embolic agent. The MVP microvascular plug (Medtronic) 
is a newer device that can be delivered via a microcatheter. 
An advantage of this device is the presence of polytetrafluo-
roethylene, which results in immediate flow occlusion with 
minimal artifact on posttreatment CTA. We typically do 
not use cyanoacrylate glue, but this is a reasonable embolic 
alternative. Onyx, glue, and coils can make subsequent 
endoleak evaluation difficult due to significant streak arti-
fact on CT imaging. In these situations, one can consider 
magnetic resonance angiography to look for a persistent 
leak where the artifact from these embolic agents can be 
minimized. It is possible that new liquid embolic agents may 
allow better results in terms of imaging.
Translumbar Embolization 
If transarterial embolization is either not feasible or 
unsuccessful in resolving the endoleak, direct translumbar 
percutaneous access into the aneurysm sac can be per-
formed. CTA is closely evaluated to determine an optimal 
site for entry such that the access needle will target the 
endoleak cavity. Our technique involves placing the patient 
in the prone position and placing a sheath needle into the 
aneurysm sac using either anatomic landmarks (ie, vertebral 
body, radiopaque markers on the endograft, calcification) 
or XperGuide software (Philips Healthcare) with cone beam 
CT. Another approach is to gain access into the aneurysm 
sac under CT guidance and subsequently move the patient 
to a fluoroscopy suite. Care is taken to avoid puncturing 
the endograft, as this may result in a type III endoleak. We 
tend to favor a left translumbar approach, if possible, to 
avoid the course of the inferior vena cava (IVC). However, 
some endoleaks may necessitate a right-sided transcaval 
approach. Incidentally, intravasated embolic material into 
the IVC may result in pulmonary embolism.
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Once the aneurysm sac is accessed and pulsatile blood is 
seen, baseline pressure measurements are obtained, which 
are subsequently compared to postembolization pressures. 
A diagnostic angiogram or “saccogram” is then obtained 
via the sheath needle to delineate the endoleak cavity and 
inflow and outflow vessels. A microcatheter is typically 
introduced coaxially to negotiate the nidus, and an attempt 
is made to catheterize every inflow and outflow vessel. If 
the latter vessels can be catheterized, coil embolization is 
performed. The endoleak sac is finally embolized with coils, 
Onyx, and/or thrombin. If it is not technically possible to 
select all of the vessels contributing to the endoleak, Onyx 
is administered under real-time fluoroscopy until there is 
embolization of the sac as well as the vessels. Thrombin 
injection into the sac is another effective alternative, but 
the inability to visualize and control the thrombin injection 
makes it less ideal. The benefit of thrombin is the absence of 
artifact on cross-sectional imaging, which allows for better 
detection of residual endoleak, but it might lead to a higher 
rate of recanalization. A final intrasac pressure measurement 
is obtained after embolization (Figure 2).
Results using this technique have been published, and 
the authors found it to be a useful bailout technique for 
persistent endoleaks after EVAR; however, endoleak recur-
rence was relatively high (50%) at a median follow-up of 39 
months, and reintervention was deemed necessary in 33% 
of cases. Repeat endoleaks following embolization were 
associated with the use of dual-antiplatelet therapy.15
Figure 2.  A patient with persistent type II endoleak despite previous embolization via a transarterial route. Translumbar direct 
sac puncture of the aortic sac is performed utilizing XperGuide software in conjunction with cone beam CT and fluoroscopic guid-
ance (A). A 20-cm sheath needle is advanced into the endoleak sac until pulsatile arterial blood flow is noted (B, C). A contrast injec-
tion (saccogram) is performed through an access needle (D). Note that coils are from the previous embolization procedure. Because 
ingress and egress vessels are not easily visualized, thrombin was injected into the sac (E). Pressure measurement via the sheath 
needle demonstrates a decrease in pressure from 81/73 to 50/48 mm Hg after embolization, with loss of pulsatility (F).
A
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Transcatheter Transcaval Approach
The transcatheter transcaval approach to the aneu-
rysm sac is uncommonly used, but it does have some 
utility, especially in the setting of a posterior endoleak 
in close proximity to the IVC, which is otherwise dif-
ficult to access. This technique is an alternative to the 
translumbar or transcaval approach. A prerequisite for 
utilizing this approach is CT evidence of close proxim-
ity or adhesion of the caval wall to the aneurysm sac. 
Furthermore, there must be sufficient space between 
the wall of the aneurysm abutting the IVC and the 
endograft to allow for entry into the endoleak cavity 
without puncturing the graft. The common femoral 
vein or internal jugular vein may be utilized for access. 
A 10-F, 40-cm reinforced sheath, identical to that used 
for transjugular intrahepatic portosystemic shunt 
procedures, is then placed. Using a combination of 
landmarks from preprocedural imaging, fluoroscopic 
imaging, and/or intravascular ultrasound, the sheath is 
wedged against the posterior caval wall. The presence 
of aortic wall calcification may limit intravascular ultra-
sound evaluation; however, it can serve as an impor-
tant fluoroscopic target. A small amount of contrast is 
injected to confirm that the sheath is against the caval 
wall. The endoleak is then accessed with a Colapinto 
needle (Cook Medical), and a 5-F cannula with cath-
eter is advanced into the endoleak sac. Once arterial 
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obtained, followed by contrast administration (sac-
cogram). Embolization is then performed similarly to 
translumbar embolization. A cavagram is obtained at 
the conclusion of embolization.
Potential complications related to this technique 
include pulmonary embolism from nontarget delivery 
of embolic material, retroperitoneal hemorrhage, and 
aortocaval fistula. If there is adhesion between the caval 
wall and aorta, retroperitoneal hemorrhage is unlikely to 
occur. According to a study published by Mansueto et al, 
these complications were not encountered.16
Surgical Treatment
Laparoscopic, robotic, and open surgical ligation 
of mesenteric, lumbar, and other offending arteries 
are options for patients in whom the endovascular 
approach fails, with persistent endoleak with aneurysm 
growth. Other surgical options include plication of the 
aneurysm and graft explantation. 
RESULTS OF PREVENTION OF TYPE II ENDOLEAK 
In an attempt to prevent subsequent type II endoleaks, 
one institution employed a protocol of embolizing all 
IMAs if they were successfully visualized and accessed 
prior to EVAR. They noted decreased rates in type II 
endoleak incidence, aneurysm sac enlargement, and 
reintervention rates at 24 months.17 Another institution 
performed intraprocedural abdominal aortic aneurysm 
sac embolization, which was shown to result in freedom 
from type II endoleak at 6 months and type II endoleak–
related reinterventions, but without demonstration of 
differences in aneurysm sac size.18 Given the time con-
straints, lack of robust data, and the fact that the major-
ity of type II endoleaks regress, aggressive preventive 
techniques have not been practical or adopted at our 
institution and are not routinely employed. That being 
said, we occasionally preemptively embolize the IMA or 
lumbar arteries if they are unusually large and/or if there 
is an “empty sac” with minimal luminal thrombus. Newer 
technology, such as the Nellix endograft (Endologix, Inc.), 
which fills the aneurysm sac with a polymer-filled endo-
bag, may decrease the incidence of type II endoleaks and 
reintervention rates.
CONCLUSION
In summary, type II endoleaks after EVAR are a com-
mon finding but are often of no clinical significance. 
However, in the setting of a persistent endoleak with 
concomitant aneurysm growth, secondary interven-
tions are indicated. Further investigation is required to 
determine the most effective approach and optimal 
embolic agent(s) to manage this complication.  n
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